Springworks Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Springworks Therapeutics Inc (SWTX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Springworks Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 220M vs 370,799M combined for its competitors (0.1% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-10.6% annualized vs trailing 12 months), vs decelerating (-22.9%) for its tracked peer group.
- Growth: Springworks Therapeutics Inc generated 133.7% revenue growth year over year in Q1 2025, vs 5.6% for its competitors combined.
- Profitability: Its -169.5% net margin compares with 11.6% for the peer group.
- Peer revenue share: Springworks Therapeutics Inc accounted for 0.1% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $2.62M compares with $1.00M for the peer group (2.6x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
SWTX Sales vs. its Competitors, Q1 2025
Springworks Therapeutics Inc reported revenue growth of 133.68 % year on year in Q1 2025, above its competitors' combined revenue growth of 5.60 %.
With a net margin of -169.47 %, Springworks Therapeutics Inc reported lower profitability than its competitors (11.64 %).
Springworks Therapeutics Inc generated 0.07 % of the combined sales of its peer group, up from 0.03 % a year earlier.
API endpoints for this dataset
Springworks Therapeutics Inc vs. its Competitors, Q1 2025
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Springworks Therapeutics Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Springworks Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Springworks Therapeutics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Springworks Therapeutics Inc's competitor groups requires a Commercial License.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 20.8% year over year, combined, vs 133.7% for Springworks Therapeutics Inc. Springworks Therapeutics Inc's share of combined industry revenue moved from 0.06% to 0.11%, a gain of 0.05 percentage points.
Springworks Therapeutics Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Springworks Therapeutics Inc | - | - | - | Yes |
| Competitors combined (19) | ||||
| High-Confidence Competitors (5) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
SWTX Stock Performance relative to its Competitors
SWTX Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Erasca Inc | 282.9% | Outperformed |
| 3 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 4 | Revolution Medicines Inc | 282.9% | Outperformed |
| 5 | Day One Biopharmaceuticals Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Springworks Therapeutics Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Springworks Therapeutics Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Springworks Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Springworks Therapeutics Inc |
3,518.86 | 219.67 |
 Eli Lilly And Company |
1,209,663.60 | 86,462.00 |
 Novartis Ag |
317,785.25 | 56,674.00 |
 Astrazeneca Plc |
291,203.66 | 58,739.00 |
 Amgen Inc |
250,468.48 | 38,095.00 |
 Gilead Sciences Inc |
208,779.39 | 30,988.00 |
| SUBTOTAL | 2,669,738.66 | 371,018.41 |
Sign in to see all competitors of Springworks Therapeutics Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Springworks Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Springworks Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from Springworks Therapeutics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Revolution Medicines, Inc. | Company report | 85% |
| Pfizer | Company report | 85% |
| BioDiscovery, Inc. | Company report | 85% |
| Vivace Therapeutics, Inc. | Company report | 85% |
| Ikena Oncology, Inc. | Company report | 85% |
| Inventiva S.A. | Company report | 85% |
| Genentech, Inc. | Company report | 85% |
| Kyowa Kirin Co., Ltd. | Company report | 85% |
| TheRas, Inc. | Company report | 85% |
| Cedilla Therapeutics | Company report | 85% |
| Wellspring Biosciences, Inc. | Company report | 85% |
| Yuhan Corporation | Company report | 85% |
| Seagen | Company report | 85% |
| Regeneron Pharmaceuticals | Company report | 85% |
| Moderna Inc | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Astrazeneca Plc | Company report | 85% |
| Erasca Inc | Company report | 85% |
| Day One Biopharmaceuticals Inc | Company report | 85% |
| Mirati Therapeutics Inc | Company report | 85% |
| Black Diamond Therapeutics Inc | Company report | 85% |
| Medicines Co | Company report | 85% |
| Kinnate Biopharma Inc | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
| Blueprint Medicines Corporation | Company report | 85% |
Company report basis, confidence, active dates and source counts for Springworks Therapeutics Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Springworks Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Amgen Inc | Reportable 100.00 % |
| Pfizer Inc | U.S. Commercial Division 58.35 % |
| Exelixis Inc | Reportable 100.00 % |
| Blueprint Medicines Corporation | Single Reportable Segment 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Springworks Therapeutics Inc .
Springworks Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Springworks Therapeutics Inc | 3,519 | 2,615,119 | -3,023,012 |
| Eli Lilly And Company | 1,209,664 | 1,729,240 | 551,594 |
| Novartis Ag | 317,785 | 752,973 | 185,566 |
| Astrazeneca Plc | 291,204 | 706,847 | 123,141 |
| Amgen Inc | 250,468 | 2,930,385 | 672,538 |
| Gilead Sciences Inc | 208,779 | 1,822,824 | -227,235 |
| PEERS TOTAL | 2,666,220 | 1,003,317 | 153,029 |
Sign in to see all peers for Springworks Therapeutics Inc .
Springworks Therapeutics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Gilead Sciences Inc | United States 76.66 % |
| Pfizer Inc | United States 63.93 % |
| Exelixis Inc | United States 92.47 % |
| Iovance Biotherapeutics inc | US 98.66 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Springworks Therapeutics Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 158 companies in Springworks Therapeutics Inc's industry classification, broader than the peer set above. Market cap in millions of $.Springworks Therapeutics Inc ranks #0 of 158 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,353, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 250,468 | 26.02 % |
| 2 | Gilead Sciences Inc | 207,444 | 21.55 % |
| 3 | Moderna Inc | 101,168 | 10.51 % |
| 4 | Argenx Se | 61,223 | 6.36 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Mesoblast Limited | 1,234 | 5.2% |
| 9 | Exelixis Inc | 1,234 | 5.2% |
| 10 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 0 | Springworks Therapeutics Inc | - | 0.00 % |
Market cap and industry share for the rest of Springworks Therapeutics Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2025-06-30.
Springworks Therapeutics Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Biotechnology & Pharmaceuticals industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (160 companies). See the full Biotechnology & Pharmaceuticals industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 25.49 % | 34.84 % (avg) | -9.3 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -2.62 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 9.17 % | 8.89 % (avg) | +0.3 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Springworks Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (160 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 27.3x | - |
| EV / EBITDA | - | 17.0x | - |
| P/B | 6.9x | 5.1x | +1.8x |
| Return on Equity | -51.10 % | industry aggregate | -58.77 % |
| Return on Invested Capital | - | -11.80 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Springworks Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - |
| Return on Invested Capital | - | -4.50 % | -15.21 % | -36.79 % | - | - |
| P/E | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Springworks Therapeutics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,353 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Moderate, in line with the industry | Capital intensity (capex / revenue) of 9.17 % vs industry average 8.89 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Springworks Therapeutics Inc's dedicated Suppliers and Customers pages, not here.
Springworks Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 58.8 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-10.6% annualized vs trailing 12 months).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (36.80 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-22.9% annualized).
Methodology: see Methodology: SWOT Analysis.
Springworks Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Springworks Therapeutics Inc | 0.97 | 5.22 | - |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Gilead Sciences Inc | - | 1.52 | 1.47 |
Sign in to see all peers for Springworks Therapeutics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Springworks Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Springworks Therapeutics Inc | Q1 2025 | +133.7 % | - |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Gilead Sciences Inc | Q3 2026 | +6.8 % | -20.4 % |
| PEERS TOTAL | +9.9 % | +16.2 % |
Sign in to see all peers for Springworks Therapeutics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Springworks Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Springworks Therapeutics Inc | Q1 2025 | +193.4 % | -94.8 % |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Gilead Sciences Inc | Q3 2026 | +0.1 % | +61.2 % |
Sign in to see all peers for Springworks Therapeutics Inc .
Springworks Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Springworks Therapeutics Inc | - | - | - |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Gilead Sciences Inc | - | - | - |
Sign in to see all peers for Springworks Therapeutics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Springworks Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Springworks Therapeutics Inc | - | 16.02 |
| Eli Lilly And Company | 43.96 | 13.99 |
| Novartis Ag | 22.73 | 5.61 |
| Astrazeneca Plc | 28.51 | 4.96 |
| Amgen Inc | 28.60 | 6.57 |
| Gilead Sciences Inc | - | 6.74 |
| PEERS AVERAGE | 47.42 | 7.20 |
Sign in to see all peers for Springworks Therapeutics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.